NYSE$PEN
Penumbra Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Penumbra reported strong Q3 2023 results with significant revenue growth and increased profitability.
Penumbra, Inc. reported a 26.8% increase in revenue to $270.9 million for Q3 2023, driven by strong growth in thrombectomy products. The company achieved a net income of $9.2 million and an adjusted EBITDA of $51.5 million.
- Revenue increased by 26.8% to $270.9 million compared to Q3 2022.
- Thrombectomy product sales grew by 38.0% to $179.1 million.
- Net income was $9.2 million, with an adjusted EBITDA of $51.5 million.
- The company expects revenue growth to accelerate to 28% to 31% year over year for Q4 2023.
Headline financials
Revenue & EPS history
Penumbra · Revenue · Quarterly
$271M
Revenue by segment
Penumbra · $271M total across 2 segments · Q3 2023
- Thrombectomy$179M—66.1%
- Embolization and Access$91.9M—33.9%
Forward guidance
The company expects total company revenue growth to accelerate to 28% to 31% year over year for the fourth quarter of 2023, correlating to the midpoint of the annual guidance range of $1.05 billion to $1.07 billion for full year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+2.0%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
57%
28 / 49 earnings
Positive
+23.4%
Q4 2014
Best reaction
-15.8%
Q2 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | -0.7% | -1.1% | |
| Q4 2025 | +0.9% | +0.4% | -1.1% | |
| Q3 2025 | +17.1% | +24.0% | +33.3% | |
| Q1 2025 | +7.0% | +6.5% | -3.7% | |
| Q4 2024 | +12.0% | +6.1% | +3.4% | |
| Q3 2024 | +9.2% | +9.5% | +16.5% | |
| Q2 2024 | -6.3% | -1.6% | +13.5% | |
| Q1 2024 | -4.0% | +0.3% | -7.2% | |
| Q4 2023 | -7.7% | -10.1% | -13.0% | |
| Q3 2023 | +2.0% | +1.3% | +17.4% | |
| Q2 2023 | -11.2% | -16.8% | -12.8% | |
| Q1 2023 | +5.5% | +8.6% | +10.1% | |
| Q4 2022 | +2.3% | -0.5% | +5.1% | |
| Q3 2022 | +3.0% | +12.0% | +34.0% | |
| Q2 2022 | +13.7% | +8.7% | +12.5% | |
| Q1 2022 | -3.6% | -15.3% | -17.6% | |
| Q4 2021 | -3.4% | +5.6% | -2.6% | |
| Q3 2021 | +3.0% | -1.8% | -14.8% | |
| Q2 2021 | -2.1% | -2.4% | +3.0% | |
| Q1 2021 | -8.3% | -8.9% | -13.9% | |
| Q4 2020 | +3.2% | +1.6% | -3.4% | |
| Q3 2020 | +10.6% | +3.9% | -5.1% | |
| Q2 2020 | +2.5% | +5.5% | -3.5% | |
| Q1 2020 | +1.4% | +2.4% | +1.4% | |
| Q4 2019 | -6.8% | -10.0% | -13.7% | |
| Q3 2019 | -0.8% | +0.6% | +1.0% | |
| Q2 2019 | -6.9% | -6.5% | -15.1% | |
| Q1 2019 | +3.0% | -0.2% | +17.8% | |
| Q4 2018 | -11.2% | -5.7% | -1.1% | |
| Q3 2018 | +7.2% | +9.0% | +1.1% | |
| Q2 2018 | -15.8% | -16.0% | -3.8% | |
| Q1 2018 | +9.5% | +10.2% | +15.7% | |
| Q4 2017 | +3.9% | +8.4% | +11.0% | |
| Q3 2017 | +9.3% | +2.3% | -3.3% | |
| Q2 2017 | +5.8% | +4.1% | +4.4% | |
| Q1 2017 | +4.3% | -2.3% | +1.0% | |
| Q4 2016 | +3.8% | +5.2% | +7.8% | |
| Q3 2016 | -2.5% | +2.4% | -4.2% | |
| Q2 2016 | +10.9% | +10.8% | +6.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q4 2013 | -6.3% | — | — | |
| Q2 2015 | -6.3% | — | — | |
| Q1 2014 | -6.3% | — | — | |
| Q3 2014 | +23.4% | — | — | |
| Q3 2015 | +23.4% | — | — | |
| Q4 2014 | +23.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro